Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55–70 Years of Age | Zendy

Karen Miernyk | Zendy; Jay C. Butler | Zendy; Lisa Bulkow | Zendy; Rosalyn Singleton | Zendy; Thomas W. Hennessy | Zendy; Catherine M. Dentinger | Zendy; Helen Peters | Zendy; Barbara Knutsen | Zendy; Jack Hickel | Zendy; Alan J. Parkinson | Zendy

Open Access

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55–70 Years of Age

Author(s) -

Karen Miernyk,

Jay C. Butler,

Lisa Bulkow,

Rosalyn Singleton,

Thomas W. Hennessy,

Catherine M. Dentinger,

Helen Peters,

Barbara Knutsen,

Jack Hickel,

Alan J. Parkinson

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/599824

Subject(s) - reactogenicity , vaccination , medicine , pneumococcal polysaccharide vaccine , pneumococcal conjugate vaccine , immunogenicity , serotype , titer , immunology , immune system , antibody , streptococcus pneumoniae , microbiology and biotechnology , biology , antibiotics , pneumococcal disease

Vaccination with conjugate vaccines stimulates T cell-dependent immunity, whereas vaccination with polysaccharide vaccines does not. Thus, vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7) followed by the 23-valent pneumococcal polysaccharide vaccine (PPV23) may offer better protection against invasive pneumococcal disease for older adults than does vaccination with PPV23 alone, which is what is currently recommended.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research